Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 9/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2399110 | 0.88 | KMT2A (0.43) | LTA4HPOLBKMT2ACACNA2D1CACNA1B | |
| SCHEMBL2397063 | 0.84 | LTA4H (0.38) | LTA4HPOLBCACNA2D1CACNA1BCACNB1 | |
| SCHEMBL2399161 | 0.82 | LTA4H (0.44) | LTA4H | |
| SCHEMBL8493732 | 0.72 | POLB (0.59) | LTA4HPOLBKMT2ACACNA2D1CACNA1B | |
| SCHEMBL8788651 | 0.69 | LTA4H (0.50) | LTA4HPOLB | |
| SCHEMBL2841877 | 0.68 | LTA4H (0.55) | LTA4HPOLBCHRNB4CHRNA3 | |
| SCHEMBL2841875 | 0.68 | LTA4H (0.55) | LTA4HPOLBCHRNB4CHRNA3 | |
| SCHEMBL2398620 | 0.68 | SCN4A (0.46) | — | |
| SCHEMBL13383566 | 0.68 | LTA4H (0.48) | LTA4HCHRNB4CHRNA3 | |
| SCHEMBL12266365 | 0.68 | LTA4H (0.48) | LTA4HPOLBCHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | LTA4H 4297/4885POLB 1280/4885KMT2A 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.